防治高同型半胱氨酸血症的新策略

作     者：耿彬 常林 杜军保 唐朝枢 GENG Bin;CHANG Lin;DU Jun-Bao;Tang Chao-shu

作者机构：北京大学第一医院心血管研究所北京100034 教育部重点实验室 北京大学基础医学院生理学系 北京大学第一医院儿科 

出 版 物：《北京大学学报（医学版）》 (Journal of Peking University:Health Sciences)

年 卷 期：2005年第37卷第2期

页      面：215-219页

核心收录：

学科分类：1007[医学-药学(可授医学、理学学位)] 1006[医学-中西医结合] 100706[医学-药理学] 1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 100602[医学-中西医结合临床] 

基　　金：国家重点基础研究发展规划项目基金 (G2000056905 )资助~~ 

主　　题：高同型半胱氨酸血症 新策略 防治 能量代谢障碍 维生素B12 甲基化反应 Hcy 甲基转移酶 蛋氨酸合酶 代谢产物 中间产物 疾病发生 动态平衡 辅助因子 甜菜碱 代谢性 机体内 腺苷 

摘      要：Hyperhomocysteinemia is an independent risk factor for cardiovascular diseases. At present, the main therapeutic provision is to supply vitamin B 6, B 12 and folic acids, and the toxic and ill effect have been reported. Homocysteine, taurine, hydrogen sulfide and metallothionein are metabolic products from methionine. Homocysteine induces necrosis of endothelium, proliferation of vascular smooth muscle cells, proliferation and activation of vascular fibroblast cells and mitochondrial structural destruction and dysfunction of myocardium cells. Taurine, an end metabolic product of homocysteine, obviously reduces cardiovascular injury induced by homocysteine. The possible mechanism of antagonism by reducing oxidative stress and endoplasmic reticulum stress has been proved. Hydrogen sulfide, another end metabolic product of homocysteine, obviously reducing cardiovascular injury of homocysteine by scavenging oxidative radicals has been found. Metallothionein a derivant production of homocysteine metabolism, antagonism to homocysteine injury to cardiovascular system been discussed. Homocysteine, taurine, hydrogen sulfide and metallothionein, as a metabolic product of methionine, interactive antagonism and interactive biological influence have been reviewed. Induced endogenous or exogenous supply of taurine, hydrogen sulfide and metallothionein might resist cardiovascular injury induced by hyperhomocysteinemia. According to the methionine metabolic cycle, using endogenous antagonistic substances might be a new clinical preventive and treatment target of homocystinemia.